Prescription medicine
Acetaminophen and oxycodone Brand names: Endocet, Prolate, Percocet, Nalocet; first approved as Xartemis Xr
Acetaminophen and oxycodone (Percocet) is a prescription medicine with an FDA approval on record since 2014. FDA's NDC Directory lists it from 29 generic labelers, and pharmacies paid $0.183 per oxycodone-acetaminophen 7.5-325 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
- Boxed warning
- DEA Schedule II
Check it at the source: the acetaminophen and oxycodone FDA label on DailyMed (effective December 23, 2025, Aurolife Pharma, LLC); the NDA 204031 record on Drugs@FDA; every acetaminophen and oxycodone label on DailyMed.
Highlights of the record
FDA label of December 23, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
ADDICTION, ABUSE, AND MISUSE: RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION,.
HEPATOTOXICITY and and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of Oxycodone and Acetaminophen Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see WARNINGS]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Oxycodone and Acetaminophen Tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Oxycodone and Acetaminophen Tablets are essential [see WARNINGS]. Accidental Ingestion Accidental ingestion of even one dose of Oxycodone and Acetaminophen Tablets, especially by children, can result in a fatal overdose of Oxycodone [see WARNINGS]. […]
Used for
From the label: indications and usageOxycodone and acetaminophen tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Forms and strengths
- 2.5 mg / 325 mg
- 2.5 mg / 300 mg
- 5 mg / 325 mg
- 5 mg / 300 mg
- 5 mg/5ml / 325 mg/5ml
- 7.5 mg / 325 mg
- 7.5 mg / 300 mg
- 10 mg / 325 mg
- 10 mg / 300 mg
- 10 mg/5ml / 300 mg/5ml
- 325 mg / 10 mg
- 325 mg / 2.5 mg
Tablet; solution.
On the market
- Earliest approval on file
- March 11, 2014 Xartemis Xr, Mallinckrodt Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 64 first August 31, 1976; 20 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 29 of which 29 under generic applications, 0 under brand applications, repackagers included
- Last listed patent
- May 16, 2032 Xartemis XR tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.183 per tablet Oxycodone-acetaminophen 7.5-325 mg tablet
- Shortage (FDA)
- None current 5 past records
- Recalls by its makers (FDA)
- 8 since 2013 0 Class I among all firms' recalls; latest December 16, 2025
- FAERS reports
- 23,353 through July 30, 2026
What is acetaminophen and oxycodone used for?
From the label: indications and usageOxycodone and acetaminophen tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see WARNINGS], reserve opioid analgesics, including oxycodone and acetaminophen tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Conditions named in the indications of acetaminophen and oxycodone's FDA labels, with every medicine labeled for each:
From other acetaminophen and oxycodone labelsPain: INDICATIONS AND USAGE Oxycodone and acetaminophen tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
FDA pharmacologic class: Opioid Agonist.
Source: FDA drug label (Oxycodone and Acetaminophen), Aurolife Pharma, LLC, effective December 23, 2025 (SPL set 69df20d9-b1d5-47dc-9ff0-29987284f8c7), via openFDA; the full label on DailyMed
Is there a generic for acetaminophen and oxycodone (Percocet)?
The FDA approved the first generic acetaminophen and oxycodone on August 31, 1976. 64 generic applications are approved; 20 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists acetaminophen and oxycodone from 29 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 12 patents for Xartemis XR tablets, the last expiring on May 16, 2032. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2014 earliest approval on file
- 1976 first generic approved
- 2032 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for acetaminophen and oxycodone (Percocet)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.183 per Oxycodone-acetaminophen 7.5-325 mg tablet, up 2% from $0.179 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Oxycodone-acetaminophen 7.5-325 mg tablet (generic)
- Percocet 5-325 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Endocet 10-325 mg tablet | Generic | $0.231 per tablet | $6.92 | -7% |
| Endocet 2.5-325 mg tablet | Generic | $0.762 per tablet | $22.85 | -33% |
| Endocet 5-325 mg tablet | Generic | $0.117 per tablet | $3.51 | -5% |
| Endocet 7.5-325 mg tablet | Generic | $0.183 per tablet | $5.48 | +2% |
| Oxycodone-acetaminophen 10-325 mg tablet | Generic | $0.231 per tablet | $6.92 | -7% |
| Oxycodone-acetaminophen 10-325 mg tablet | Generic | $0.231 per tablet | $6.92 | -7% |
| Oxycodone-acetaminophen 2.5-325 mg tablet | Generic | $0.762 per tablet | $22.85 | -33% |
| Oxycodone-acetaminophen 5-325 mg tablet | Generic | $0.117 per tablet | $3.51 | -5% |
| Oxycodone-acetaminophen 5-325 mg tablet | Generic | $0.117 per tablet | $3.51 | -5% |
| Oxycodone-acetaminophen 7.5-325 mg tablet | Generic | $0.183 per tablet | $5.48 | +2% |
| Percocet 10-325 mg tablet | Brand | $41.40 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $1,241.86 | -0.2% |
| Percocet 5-325 mg tablet | Brand | $29.32 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $879.50 | -0.2% |
| Percocet 7.5-325 mg tablet | Brand | $31.60 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $948.14 | -0.6% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is acetaminophen and oxycodone in shortage?
No acetaminophen and oxycodone presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 5 records are all marked to be discontinued, the latest updated November 3, 2025. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70) | Endo Pharmaceuticals, Inc. | To Be Discontinued | November 3, 2025 |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70) | Endo Pharmaceuticals, Inc. | To Be Discontinued | November 3, 2025 |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70) | Endo Pharmaceuticals, Inc. | To Be Discontinued | November 3, 2025 |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85) | Endo Pharmaceuticals, Inc. | To Be Discontinued | November 3, 2025 |
| Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70) | Endo Pharmaceuticals, Inc. | To Be Discontinued | November 3, 2025 |
Every acetaminophen and oxycodone presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has acetaminophen and oxycodone been recalled?
The FDA's Enforcement Report lists 8 recalls naming acetaminophen and oxycodone since 2013: 0 Class I (the most serious), 6 Class II, 2 Class III; 2 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 16, 2025 | Class II | SpecGx, LLC | Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets. |
| March 18, 2020 | Class II | Aurobindo Pharma USA Inc. | CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed |
| August 21, 2018 | Class III | Mayne Pharma Inc | Labeling: Incorrect or Missing Lot and/or Exp Date: Lot FG10517 is mislabeled on the primary container with Lot FG01517, shipper labels and invoices contain … |
| August 28, 2014 | Class II | Alvogen, Inc | Failed Content Uniformity Specifications - The lot failed to meet the acceptance criteria for Uniformity of Dosage Units at the time of release for the … |
| August 27, 2014 | Class II | Qualitest Pharmaceuticals | Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles. |
| September 13, 2013 | Class II | Watson Laboratories Inc | Presence of Foreign Tablets/Capsules: 20 tablets of Oxycodone/APAP 7.5/500 mg were found in a sealed 100 count bottle of Oxycodone and Acetaminophen Tablets … |
| July 19, 2013 | Class III | Watson Laboratories Inc | Subpotent drug: Two lots of Oxycodone and Acetaminophen Capsules, USP 5/500 mg are being recalled due to low out of specification (OOS) assay result obtained … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the acetaminophen and oxycodone label say about other medicines?
The acetaminophen and oxycodone label names 26 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Buprenorphine | warnings | Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including oxycodone and acetaminophen tablets. |
| Butorphanol | drug interactions | Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics The concomitant use of opioids with other opioid analgesics, such as butorphanol, nalbuphine, pentazocine, may reduce the analgesic effect of oxycodone and acetaminophen tablets and/or precipitate withdrawal symptoms. |
| Carbamazepine | drug interactions | Inducers of CYP3A4 The concomitant use of oxycodone and acetaminophen tablets and CYP3A4 inducers, such as rifampin, carbamazepine, and phenytoin, can decrease the plasma concentration of oxycodone [see CLINICAL PHARMACOLOGY], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have … |
| Cyclobenzaprine | drug interactions | … serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone),and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin … |
| Erythromycin | drug interactions | Drug Interactions Inhibitors of CYP3A4 and CYP2D6 The concomitant use of oxycodone and acetaminophen tablets and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. … |
| Gabapentin | warnings | … non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids, [gabapentin or pregabalin] and other opioids). |
| Ketoconazole | drug interactions | Drug Interactions Inhibitors of CYP3A4 and CYP2D6 The concomitant use of oxycodone and acetaminophen tablets and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. … |
| Lamotrigine | drug interactions | Lamotrigine Serum lamotrigine concentrations may be reduced, producing a decrease in therapeutic effects. |
| Linezolid | drug interactions | … monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; |
| Metaxalone | drug interactions | … neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone),and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome … |
| Methylene blue | drug interactions | … inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; |
| Mirtazapine | drug interactions | … (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone),and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as … |
| Nalbuphine | drug interactions | Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics The concomitant use of opioids with other opioid analgesics, such as butorphanol, nalbuphine, pentazocine, may reduce the analgesic effect of oxycodone and acetaminophen tablets and/or precipitate withdrawal symptoms. |
| Nalmefene | warnings | Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose I nform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). |
Every other medicine the acetaminophen and oxycodone label names
| Medicine named | Section | What the label says |
|---|---|---|
| Naloxone | warnings | Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose I nform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). |
| Phenelzine | drug interactions | Monoamine Oxidase Inhibitors (MAOIs) The concomitant use of opioids and MAOIs, such as phenelzine, tranylcypromine, linezolid, may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory … |
| Phenytoin | drug interactions | Inducers of CYP3A4 The concomitant use of oxycodone and acetaminophen tablets and CYP3A4 inducers, such as rifampin, carbamazepine, and phenytoin, can decrease the plasma concentration of oxycodone … |
| Pregabalin | warnings | … general anesthetics, antipsychotics, gabapentinoids, [gabapentin or pregabalin] and other opioids). |
| Probenecid | drug interactions | Probenecid Probenecid may increase the therapeutic effectiveness of acetaminophen slightly. |
| Propranolol | drug interactions | Beta Blockers (Propranolol) Propranolol appears to inhibit the enzyme systems responsible for the glucuronidation and oxidation of acetaminophen. |
| Rifampin | drug interactions | Inducers of CYP3A4 The concomitant use of oxycodone and acetaminophen tablets and CYP3A4 inducers, such as rifampin, carbamazepine, and phenytoin, can decrease the plasma concentration of oxycodone … |
| Ritonavir | drug interactions | … azole-antifungal agents (e.g. ketoconazole), and protease inhibitors (e.g., ritonavir), can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. |
| Tramadol | drug interactions | … the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone),and monoamine oxidase (MAO) inhibitors (those intended to … |
| Tranylcypromine | drug interactions | Monoamine Oxidase Inhibitors (MAOIs) The concomitant use of opioids and MAOIs, such as phenelzine, tranylcypromine, linezolid, may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory … |
| Trazodone | drug interactions | … that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone),and monoamine oxidase (MAO) inhibitors (those … |
| Zidovudine | drug interactions | Zidovudine The pharmacologic effects of zidovudine may be decreased because of enhanced non-hepatic or renal clearance of zidovudine. |
Source: FDA drug label (Oxycodone and Acetaminophen), Aurolife Pharma, LLC, effective December 23, 2025 (SPL set 69df20d9-b1d5-47dc-9ff0-29987284f8c7), via openFDA; the full label on DailyMed
What do FAERS reports show for acetaminophen and oxycodone?
The FDA Adverse Event Reporting System holds 23,353 reports that list acetaminophen and oxycodone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2,983 are coded as a death and 4,385 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2023 (9,274, against a median of 1,209 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as acetaminophen and oxycodone?
27 other medicines are given the same way (oral) and in the same FDA class as acetaminophen and oxycodone or labeled mainly for the same use (pain), the same class first. Pain lists all 80 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Tramadol | Pain | 40 labelers | $0.0248 per tablet 50 mg tablet | No current entry |
| Morphine | Pain | 17 labelers | $0.226 per tablet 15 mg tablet | In shortage |
| Hydromorphone | Pain | 11 labelers | $0.219 per tablet 4 mg tablet | In shortage |
| Methadone | Pain | 17 labelers | $0.177 per tablet 10 mg tablet | No current entry |
| Oxymorphone | Pain | 9 labelers | n/a | No current entry |
| Tapentadol | Pain | 4 labelers | $14.48 per tablet 100 mg tablet | No current entry |
| Hydrocodone | Pain | 1 labeler | $7.95 per capsule 15 mg capsule | No current entry |
| Levorphanol | Pain | 7 labelers | $10.65 per tablet 2 mg tablet | No current entry |
Every medicine labeled for the same conditions as acetaminophen and oxycodone
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to acetaminophen and oxycodone
- 27 medicines for the same use
- Other opioids
- the pharmacologic class, with prices and generics
- Acetaminophen and oxycodone side effects
- the label's list beside FAERS reports
- Acetaminophen and oxycodone shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other